Publication date context 19 February 2026. A regulatory update confirms Genoss Co., Ltd. has opened enrollment by invitation for a new vascular device trial using the GENOSS PCB for femoropopliteal artery disease treated with percutaneous transluminal angioplasty. This update is relevant to clinicians performing PTA, device manufacturers, and regulatory professionals monitoring device trials. The ClinicalTrials.gov record NCT07399080 provides the official overview.
What changed in the trial status?
The ClinicalTrials.gov record NCT07399080 shows enrollment by invitation for a GENOSS PCB device aimed at treating femoropopliteal artery disease during PTA. The sponsor is Genoss Co., Ltd. This update notes a shift from open recruitment to invitation based participation. The change affects who may access enrollment and how enrollment data is collected for this study. Stakeholders including physicians, trial managers, and regulators should track the official trial page for enrollment criteria and updates. The move to invitation only can influence generalizability and require clear site procedures to manage consent, safety checks, and data integrity.
What is the GENOSS PCB device and what is its intended use?
The GENOSS PCB is a vascular device under investigation for femoropopliteal artery disease. In this trial it is used in conjunction with percutaneous transluminal angioplasty to treat narrowed or occluded segments within the femoral and popliteal arteries. The listing credits Genoss Co., Ltd as the sponsor and identifies the device as the subject of this clinical investigation. The description underscores that this is a research study and does not represent confirmed clinical results at this time. The public record does not specify a formal regulatory class in the listing, which is typical for early stage device investigations.
What are the trial features and regulatory context?
The trial targets femoropopliteal artery disease in the context of PTA. The sponsor is Genoss Co., Ltd. The official listing appears on ClinicalTrials.gov with identifier NCT07399080. Enrollment is described as by invitation, which means access is controlled and may depend on site readiness and sponsor criteria. No effectiveness outcomes are reported in the listing. The article presents this information to inform clinicians, regulators, and device developers about the current status of the trial and its governance framework. Regulatory observers will look for adherence to informed consent, safety monitoring, and transparent reporting of trial updates through the registry.
Who is eligible and how enrollment works?
Enrollment by invitation indicates potential participants are selected by the sponsor or the study site. The source text does not provide explicit inclusion or exclusion criteria. It also does not provide participant numbers or anticipated timelines. Clinicians should consult the ClinicalTrials.gov entry for the official eligibility criteria and recruitment status. The note is intended to help readers understand how this trial fits into the broader landscape of device based vascular interventions in PTA settings. Stakeholders should prepare for potential changes as the study progresses and consider how invitation criteria may affect safety monitoring and informed consent processes.
- 1. What is the GENOSS PCB?
A vascular device under investigation for femoropopliteal artery disease used in percutaneous transluminal angioplasty. - 2. What does enrolling by invitation mean?
Participants are preselected by the sponsor or site rather than recruited publicly. - 3. Where can I find the official trial record?
The record is on ClinicalTrials.gov with identifier NCT07399080 and is accessible at https://clinicaltrials.gov/study/NCT07399080?term=medical+device.
In summary, the trial indicates an invitation only enrollment for the GENOSS PCB device in femoropopliteal disease. Regulators and clinicians should monitor the ClinicalTrials.gov page for updates to enrollment status and any safety notices. The information supports careful data collection, robust consent practices, and ongoing assessment of device related risk in the context of PTA.
This information is intended for professionals and is not legal advice. For decisions about patient care or regulatory compliance, consult the full trial record and applicable regulatory guidance.
https://clinicaltrials.gov/study/NCT07399080?term=medical+device